Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

(2018) Hiddo J. L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers

(2016) H. J. L. Heerspink et al.   DIABETES OBESITY & METABOLISM

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

(2016) David Cherney et al.   DIABETOLOGIA

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

(2016) Paola Fioretto et al.   DIABETOLOGIA

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

(2016) Hiddo J. L. Heerspink et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study

(2016) Michael A Weber et al.   Lancet Diabetes & Endocrinology

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

(2015) William T. Cefalu et al.   DIABETES CARE

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise

(2014) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 28-Week Extension

(2014) Lawrence A. Leiter et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

(2013) John P.H. Wilding   ANNALS OF INTERNAL MEDICINE

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2013) Serge A. Jabbour et al.   DIABETES CARE

Renal Transport of Uric Acid: Evolving Concepts and Uncertainties

(2012) Ion Alexandru Bobulescu et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

(2012) J. Rosenstock et al.   DIABETES CARE

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

(2012) R. R. Henry et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET